AdvanCell
About:
AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
Website: https://advancell.com.au/
Twitter/X: _advancell_iso
Top Investors: Morningside Venture Investments, NSW Health
Description:
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
Total Funding Amount:
$14.6M
Estimated Revenue Range:
$10M to $50M
Headquarters Location:
Sydney, New South Wales, Australia
Founded Date:
2019-01-01
Founders:
Number of Employees:
11-50
Last Funding Date:
2022-08-23
IPO Status:
Private
Industries:
© 2025 bioDAO.ai